Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia

The Wilms Tumor gene (WT1) encodes a transcription factor involved in kidney development and malignancy. WT1 expression in a subpopulation of early CD34+ cells has suggested its involvement in hematopoiesis. WT1 is aberrantly expressed in leukemias. High expression of WT1 at diagnosis has been associated with unfavorable prognosis in adult acute myeloid leukemia (AML). The prognostic relevance of WT1 expression in pediatric AML was evaluated in only one study, including 47 patients, which showed that very low levels of WT1 at presentation were associated with an excellent outcome. To test the validity of these findings we measured levels of WT1 in 41 newly diagnosed pediatric AML of the non‐M3 FAB subtype.

[1]  W. Hiddemann,et al.  Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.

[2]  T. Naoe,et al.  Multiplex Real-time RT–PCR for Prospective Evaluation of WT1 and Fusion Gene Transcripts in Newly Diagnosed De Novo Acute Myeloid Leukemia , 2004, Leukemia & lymphoma.

[3]  J. Rowe,et al.  The relationship of patient age to the pathobiology of the clonal myeloid diseases. , 2004, Seminars in oncology.

[4]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[5]  Marcos Borato Viana,et al.  Leucemia mielóide aguda na criança: experiência de 15 anos em uma única instituição , 2003 .

[6]  K. Tobal,et al.  Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia , 2003, British journal of haematology.

[7]  A. Levis,et al.  Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Cilloni,et al.  Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients , 2002, Leukemia.

[9]  O. Hrusak,et al.  Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry , 2002, Leukemia.

[10]  N. Hosen,et al.  patients with hematopoietic malignancies product in WT 1 Humoral immune responses against Wilms tumor gene , 2002 .

[11]  Wei Huang,et al.  Utility of WT1 as a Reliable Tool for the Detection of Minimal Residual Disease in Children with Leukemia , 2002, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[12]  D. Haber,et al.  The Wilms tumor suppressor WT1 directs stage‐specific quiescence and differentiation of human hematopoietic progenitor cells , 2001, The EMBO journal.

[13]  D. Haber,et al.  Wilms tumor and the WT1 gene. , 2001, Experimental cell research.

[14]  L. Frati,et al.  Wilms' Tumor Gene Expression by Normal and Malignant Human B Lymphocytes , 2000, Leukemia & lymphoma.

[15]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[16]  B. Kornhuber,et al.  wt1 Gene Expression in Childhood Leukemias , 1999, Acta Haematologica.

[17]  G. Heinze,et al.  Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol , 1999, European journal of haematology.

[18]  玉置 広哉 The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes , 1999 .

[19]  G. Kong,et al.  Expression of Wilms tumor gene (WT1) in children with acute leukemia. , 1999, Pediatric hematology and oncology.

[20]  M. Tomonaga,et al.  The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes , 1999, Leukemia.

[21]  G. Henze,et al.  Definition of a standard‐risk group in children with AML , 1999, British journal of haematology.

[22]  F. Watzinger,et al.  Multiplex PCR for quality control of template RNA/cDNA in RT-PCR assays , 1998, Leukemia.

[23]  U. Maurer,et al.  Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. , 1997, Blood.

[24]  U. Maurer,et al.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. , 1997, Experimental hematology.

[25]  U. Maurer,et al.  High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. , 1997, Blood.

[26]  H. Menssen,et al.  Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. , 1997, Blood.

[27]  G. Heinze,et al.  Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia , 1997, Leukemia.

[28]  P. Baird,et al.  Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. , 1997, Experimental hematology.

[29]  Y. Sonoda,et al.  Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.

[30]  T. Kyo,et al.  Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. , 1996, Blood.

[31]  S. Santillana,et al.  High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. , 1996, Blood.

[32]  E. Thiel,et al.  Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. , 1995, Leukemia.

[33]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[34]  G. Saunders,et al.  Expression of the Wilms' tumor gene (WT1) in human leukemias. , 1992, Leukemia.

[35]  D. Haber,et al.  WT1: a novel tumor suppressor gene inactivated in Wilms' tumor. , 1992, The New biologist.

[36]  J. Ritter,et al.  Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. , 1990, Blood.

[37]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[38]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[39]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[40]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[41]  P. Bolufer,et al.  Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. , 2004, Haematologica.

[42]  S. Preston‐Martin,et al.  High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. , 1996, Blood.

[43]  A. Hagenbeek,et al.  Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.

[44]  M. Viana,et al.  Acute myeloid leukemia in childhood : fifteen-year experience in a single institution , 2022 .